Our drug repurposing computational platform Cloudscreen, adopts next gen algorithms for drug repurposing and provides AI powered predictions towards novel indications for existing drugs, coupled with state-of-the-art validation tools. Cloudscreen is currently being...
NEWS
Cloudpharm announces strategic partnership with Cosmos Holdings
We are very excited to announce the partnership with Cosmos Holdings (NASDAQ:COSM), to develop new products targeting the gut microbiome. Our mission is closely aligned with Cosmos, as they are devoted to developing new and innovative products using high-quality...
Cloudpharm gets funding for drug repurposing platform, Cloudscreen
Cloudpharm announces the approval of the funded project “Cloudscreen” in collaboration with the Institute of Chemical Biology of the National Hellenic Research Foundation (NHRF). The objective of the project is the development of a next generation “one-stop-shop”...
OSTEOME Project initiated, aiming at the development of a microbiome targeting dietary supplement
Cloudpharm announces the approval of the funded project “OSTEOME” in collaboration with the Musculoskeletal Diseases Research Laboratory “Th. Garofalidis ”of the Medical School of EKPA, the Institute of Chemical Biology of the National Research Foundation (NHRF), the...
Editorial on “How far have we come with contextual data integration in drug discovery”
In this editorial, we argue for a holistic view of evidence-based practices via the synergy of human and artificial intelligence in drug discovery. This strategy may build a collaborative conceptual framework to enable better-informed and rapid decisions, and the...
Publication on as new leads for the treatment of candidiasis
In this work, Cloupharm has been involved in the discovery of four compounds through a virtual screening procedure as putative sterol 14α-demethylase (CYP51) Candida albicans inhibitors. The compounds had the ability to inhibit growth of C. albicans cells and one was...